Retirement Systems of Alabama increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 88,915 shares of the medical research company’s stock after buying an additional 255 shares during the period. Retirement Systems of Alabama’s holdings in Charles River Laboratories International were worth $8,994,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Charles River Laboratories International by 12,573.1% in the first quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock valued at $345,915,000 after buying an additional 3,815,298 shares during the last quarter. FMR LLC boosted its position in Charles River Laboratories International by 39.7% in the first quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock valued at $223,806,000 after buying an additional 707,612 shares during the last quarter. Ariel Investments LLC boosted its position in Charles River Laboratories International by 30.7% in the first quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock valued at $185,335,000 after buying an additional 483,564 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new position in Charles River Laboratories International during the first quarter valued at $39,355,000. Finally, Marshall Wace North America L.P. bought a new position in Charles River Laboratories International during the first quarter valued at $39,355,000. 95.81% of the stock is owned by institutional investors.

Charles River Laboratories International, Inc. (NYSE CRL) opened at 97.97 on Friday. The stock has a market capitalization of $4.66 billion, a PE ratio of 25.82 and a beta of 1.02. Charles River Laboratories International, Inc. has a 52 week low of $67.20 and a 52 week high of $102.32. The firm has a 50 day moving average of $99.80 and a 200-day moving average of $91.67.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to analysts’ expectations of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the prior year, the business earned $1.20 earnings per share. On average, equities analysts predict that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

Charles River Laboratories International announced that its Board of Directors has initiated a share buyback plan on Wednesday, May 10th that permits the company to repurchase $150.00 million in shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: “Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Retirement Systems of Alabama” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/charles-river-laboratories-international-inc-nysecrl-shares-bought-by-retirement-systems-of-alabama/1480897.html.

Several equities analysts recently weighed in on CRL shares. Citigroup Inc. reaffirmed a “neutral” rating and set a $104.00 target price (up from $91.00) on shares of Charles River Laboratories International in a research note on Wednesday, June 28th. Jefferies Group LLC reaffirmed a “buy” rating and set a $106.00 target price on shares of Charles River Laboratories International in a research note on Friday, April 21st. Credit Suisse Group reaffirmed a “neutral” rating and set a $95.00 target price (up from $89.00) on shares of Charles River Laboratories International in a research note on Tuesday, June 6th. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Finally, BidaskClub cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $96.94.

In related news, insider Davide Molho sold 10,976 shares of the company’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $92.84, for a total value of $1,019,011.84. Following the completion of the sale, the insider now owns 27,525 shares of the company’s stock, valued at $2,555,421. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director George Massaro sold 3,830 shares of the company’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $100.81, for a total transaction of $386,102.30. Following the completion of the sale, the director now directly owns 18,731 shares of the company’s stock, valued at approximately $1,888,272.11. The disclosure for this sale can be found here. Insiders sold 79,369 shares of company stock valued at $7,846,412 over the last quarter. Company insiders own 2.20% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.